Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensitrelvir vs molnupiravir in mild/moderate COVID-19 with risk factors for severe disease
jRCTs071230014Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Ensitrelvir arm with Molnupiravir arm (2 arms). Primary endpoint: Change from baseline in SARS-CoV-2 viral RNA on Day 4. Started Jun 2023; status: completed.
02
Drugs
ensitrelvirmolnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs071230014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230014.